Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme...
Saved in:
Main Authors: | Hoimark L, Laursen T, Rungby J |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
by: Petersen AB, et al.
Published: (2013) -
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
by: Scott D
Published: (2013) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
by: Gallwitz B
Published: (2013) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann KV, et al.
Published: (2014) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016)